Cargando…

General disease costing principles

The term “disease costing” applies to those economic appraisal methodologies that ascertain the cost borne by a community because of a disease. This approach has been used to calculate the social and economic costs, in terms of loss of productivity, caused by a disease that only in the most serious...

Descripción completa

Detalles Bibliográficos
Autores principales: Sofio, Amalia Donia, Mazzuca, Franco, Mennini, Francesco S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag Italia 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611694/
http://dx.doi.org/10.1007/s101940300010
_version_ 1782264563960381440
author Sofio, Amalia Donia
Mazzuca, Franco
Mennini, Francesco S.
author_facet Sofio, Amalia Donia
Mazzuca, Franco
Mennini, Francesco S.
author_sort Sofio, Amalia Donia
collection PubMed
description The term “disease costing” applies to those economic appraisal methodologies that ascertain the cost borne by a community because of a disease. This approach has been used to calculate the social and economic costs, in terms of loss of productivity, caused by a disease that only in the most serious cases results in the death of an individual. The production losses, also defined as indirect costs, are not the only social costs caused by diseases. In addition we point also to the negative variations that are reflected onto two fundamental quantities: consumption of resources and state of health. In addition to production losses and consumption of resources, the third group is unquestionably the most important in the healthcare sector, since it deals directly with variations in the state of health. This group is denoted by the term “human costs”. In the headache field, we are far behind other pathologies, where there is a greater knowledge of the economic aspects of both the pathology-related costs and the likely benefits resulting from different therapeutical approaches. Notwithstanding the disease costing problems that are also reflected in the cost-benefit techniques, it is important for the economic analysis to gain ground since there is a growing need to keep account of the available resources and the results attainable in the healthcare policies, from the central to the peripheral levels, where the valuation tools prove even more expedient.
format Online
Article
Text
id pubmed-3611694
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Springer-Verlag Italia
record_format MEDLINE/PubMed
spelling pubmed-36116942013-04-01 General disease costing principles Sofio, Amalia Donia Mazzuca, Franco Mennini, Francesco S. J Headache Pain Pharmacoeconomy The term “disease costing” applies to those economic appraisal methodologies that ascertain the cost borne by a community because of a disease. This approach has been used to calculate the social and economic costs, in terms of loss of productivity, caused by a disease that only in the most serious cases results in the death of an individual. The production losses, also defined as indirect costs, are not the only social costs caused by diseases. In addition we point also to the negative variations that are reflected onto two fundamental quantities: consumption of resources and state of health. In addition to production losses and consumption of resources, the third group is unquestionably the most important in the healthcare sector, since it deals directly with variations in the state of health. This group is denoted by the term “human costs”. In the headache field, we are far behind other pathologies, where there is a greater knowledge of the economic aspects of both the pathology-related costs and the likely benefits resulting from different therapeutical approaches. Notwithstanding the disease costing problems that are also reflected in the cost-benefit techniques, it is important for the economic analysis to gain ground since there is a growing need to keep account of the available resources and the results attainable in the healthcare policies, from the central to the peripheral levels, where the valuation tools prove even more expedient. Springer-Verlag Italia 2003-03 /pmc/articles/PMC3611694/ http://dx.doi.org/10.1007/s101940300010 Text en © Springer-Verlag Italia 2003
spellingShingle Pharmacoeconomy
Sofio, Amalia Donia
Mazzuca, Franco
Mennini, Francesco S.
General disease costing principles
title General disease costing principles
title_full General disease costing principles
title_fullStr General disease costing principles
title_full_unstemmed General disease costing principles
title_short General disease costing principles
title_sort general disease costing principles
topic Pharmacoeconomy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611694/
http://dx.doi.org/10.1007/s101940300010
work_keys_str_mv AT sofioamaliadonia generaldiseasecostingprinciples
AT mazzucafranco generaldiseasecostingprinciples
AT menninifrancescos generaldiseasecostingprinciples